USDA grants conditional approval for first therapeutic vaccine for the treatment of cancerMerial.

USDA grants conditional approval for first therapeutic vaccine for the treatment of cancerMerial, the world leader in animal health, the conditional approval won by the U.S. Department of Agriculture for a breakthrough vaccine canine melanoma to treat a common yet deadly form of cancer in dogs. This is the first time that the U.S. Government has approved a therapeutic vaccine for the treatment of cancer – in animals or humans.

This therapeutic vaccine is an adjunct therapy for dogs that have been diagnosed with this often fatal disease. .

The vaccine will be initially for use by specialists practicing veterinary oncology, so pet owners want their veterinarians about how how to access this treatment option.The vaccine through a partnership between through a partnership between Merial, Memorial Sloan – Kettering Cancer Center and The Animal Medical Center of New York. Alan Houghton and Jedd Wolchok of MSKCC were doing laboratory testing of a melanoma vaccine they developed. A study by Dr. Philip Bergman of AMC, seeking new treatments for canine melanoma resulted in a clinical trial of the Memorial Sloan – Kettering melanoma vaccine at The Animal Medical Center.While this study proposed that co combinations of these medications is no longer effective as the either individually, the serial communication, particular the use of bisphosphonate by , not investigated, said Black and.

Rather, the results suggest that simultaneous use of alendronate is to reduce bone – building or anabolic action of parathyroid hormone. – ‘We are in early stages of use to is a new generation of bones – structure drugs osteoporosis,’said UCSF Professor Dennis Black, lead investigator.